The race for funding never stops in biopharma. 48 companies pulled in a massive amount of capital through private deals, post-IPO financing, and grants. Here's a look at who's fueling the next wave of healthcare innovation:
Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)
FIG. 1. Recent Biotech Funding Activity.
– Private Funding –
Reunion Neuroscience
💸 Announced $103M series A financing Co-Led by MPM BioImpact and Novo Holdings.
Enlaza Therapeutics
💸 Raised $100M series A financing, led by the Life Sciences Group of J.P. Morgan Private Capital.
Latus Bio
💸 Secured $54M series A funding from Samsung Life Science.
SynOx Therapeutics
💸 Secured up to $35M debt financing with Hercules Capital to progress development and commercialization of Emactuzumab.
Ennogen
💸 Secured £30M funding from Santander UK. Funds will be partly used to invest in bolt-on pharmaceutical products in complementary therapeutic areas and target future acquisitions.
4P-Pharma
💸 Raised €15M from private investors to develop therapies for untreated serious diseases.
Remepy
💸 Closed $15M seed funding led by NFX and other investors.
Infinitopes
💸 Secured £12.8M seed financing to enhance its Precision ImmunomicsTM antigen discovery technologies to target five more cancers.
Transcripta Bio
💸 Raised $10M from various investors to advance drug discovery and development.
Denovo Biopharma
💸 Awarded $11.8M grant from CIRM for the development of DB107 in high-grade glioma including glioblastoma.
Locate Bio
💸 Raised £9.2M from Mercia Ventures and BGF to fund LDGraft ALIF study.
CIRC Biosciences
💸 Completed $7M debt financing.
Liberate Medical
💸 Received $6.5M grant from the US DoD to further their PREVENT study of VentFree.
Vedanta Biosciences
💸 Awarded $3.9M funding from the CARB-X to advance its VE-707 preclinical development program.
Innovative BioTherapies
💸 Received $3.6M NIH grant study the selective cytopheretic device in adult patients with severe chronic heart failure.
TAXIS Pharmaceuticals
💸 Announces $2.67M NIH grant to advance R&D of combo therapy to combat antibiotic-resistant Pneumonia.
CellChorus
💸 Awarded $2.5M SBIR fast-track grant by the NCATS to develop TIMING™ kits for manufacturing analytics.
Surf Bio
💸 Announced $1.6M grant to advance monoclonal antibody development and reach low- and
middle-income countries.
InFlectis BioScience
💸 Awarded $650K grant from the NMSS to advance IFB-048 preclinical development in MS.
Altitude Lab
💸 Secured Small Business Administration Growth Fund Accelerator grant to launch Horizon, a commercialization partnering program.
AnDiConBio
💸 Completed hundreds of millions of yuan (RMB) in series A financing.
RS BioTherapeutics
💸 Launched crowd-funding campaign StartEngine to fund the development of RSBT-001 in COPD and IPF.
Gel4Med
💸 Awarded funding from the CDMRP/DoD in a strategic collaboration to conduct spinal cord injury research.
Ayana Bio
💸 Received grant from NIH-NCCIH to develop potential therapy for several neurological diseases.
Traverse Biotech
💸 Received Ph1 SBIR grant from NIH-NIAID to support the development of the oral innate stimulation modality for immunotherapy.
– Post-IPO/Public Funding –
Novocure
🏦 Completed $400M multi-tranche debt financing from Pharmakon to support NSCLC space launch.
BridgeBio
🏦 Launched BridgeBio Oncology Therapeutics with $200M capitalization to develop novel oncology pipeline.
Soleno Therapeutics
🏦 Announced $138M public offering to advance the development of DCCR tablets for the treatment of PWS.
Context Therapeutics
🏦 Announced $100M private placement
Abeona Therapeutics
🏦 Announced $75M offering to fund preparations for resubmission of its BLA and for commercialization of pz-cel.
ExpreS2ion
🏦 Announced SEK 60M rights issuance of units to advance ES2B-C001 and other drug pipeline candidate development.
Arrowhead Pharmaceuticals
🏦 Earned $50M milestone payment from royalty pharma due to the completion of enrollment of the Ph3 OCEAN(a) trial of Olpasiran.
Aileron Therapeutics
🏦 Announced $40M underwritten offering.
Corvus Pharmaceuticals
🏦 Announced $30.6M direct offering.
Daré Bioscience
🏦 Secured $22M royalty financing to advance Ph3 trial of women’s health product candidate.
Citius Pharmaceuticals
🏦 Closed $15M public offering.
BioVie
🏦 Awarded $13.1M funding from US DoD to evaluate NE3107 for treatment of long COVID.
Cyclacel Pharmaceuticals
🏦 Completed $8M private placement.
Predictive Oncology
🏦 Received $6.2M Phase 2B grant from the US DoD.
22nd Century Group
🏦 Redeemed $5.2M in outstanding principal and interest associated with the Omnia subordinated note and outstanding warrants.
TFF Pharmaceuticals
🏦 Completed $4.8M public offering.
Avenue Therapeutics
🏦 Reported $4.4M exercise of warrants.
Aditxt Therapeutics
🏦 Announced $4.2M private placement.
Palisade Bio
🏦 Announced $4M private placement.
Mustang Bio
🏦 Closed $4M public offering.
Lineage Cell Therapeutics
🏦 Received grant from CIRM to support the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").
---
Article History:
RF, DV, DG (05/07/24)
This article is not investment or legal advice.
Comments